Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jing Ceih Shern Yuan (also referred to by the code name OA1) is a Traditional Chinese Medicine (TCM) herbal formula investigated for the treatment of osteoarthritis, particularly of the knee and hip. Developed and studied by researchers at Chung Shan Medical University in Taiwan, the formula is typically administered as an extract in capsule or pill form. It is designed to alleviate joint pain and improve physical function in patients with degenerative joint diseases. Clinical evaluation, including a randomized, double-blind, placebo-controlled Phase 2/3 trial (NCT00411177), has focused on its efficacy in reducing WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores and its safety profile. As a multi-herb TCM product, its therapeutic effects are likely mediated through anti-inflammatory and analgesic pathways involving various phytochemical constituents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jing Ceih Shern Yuan.